Study Summary
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Interested in this trial?
Submit an InquiryInterventions
WU-CART-007BIOLOGICAL
A single IV infusion of WU-CART-007
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope | Duarte | California | United States |
| Children's Hospital Los Angeles | Los Angeles | California | United States |
| Colorado Blood Cancer Institute | Denver | Colorado | United States |
| H. Lee Moffitt Cancer Center and Research Institute Hospital | Tampa | Florida | United States |
| Washington University Saint Louis | St Louis | Missouri | United States |
| Oncology Hematology Care | Cincinnati | Ohio | United States |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States |
| TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy | Nashville | Tennessee | United States |
| MD Anderson Cancer Center | Houston | Texas | United States |
| Sarah Cannon Transplant and Cellular Therapy Methodist Hospital | San Antonio | Texas | United States |
| Sarah Cannon, Virginia Oncology Associates | Norfolk | Virginia | United States |
| Seattle Children's Hospital | Seattle | Washington | United States |
| Peter Mac Callum Cancer Institute | Melbourne | Victoria | Australia |
| Royal Children's Melbourne | Melbourne | Victoria | Australia |